Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar S Patel

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Cancer|April 6, 2023
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myelomaNaresh Bumma, Binod Dhakal, Raphael Fraser, et al.
Cancer Discovery|April 7, 2024
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell CarcinomaSumanta K Pal, Ben Tran, John B A G Haanen, et al.
Blood|December 12, 2025
Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trialEverett Meyer, Amandeep Salhotra, Arpita Gandhi, et al.
Blood|March 3, 2026
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomaJennifer L Crombie, Sairah Ahmed, Matthew J Frigault, et al.
Transplantation and Cellular Therapy|September 29, 2021
Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic SyndromeAnurag Singh, Christopher E Dandoy, Min Chen, et al.
JCO Precision Oncology|October 23, 2025
Remission of <i>TP53</i>-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33)Guenther Koehne, Muhammad U Mushtaq, Lori S Muffly, et al.
Nature Medicine|May 12, 2026
CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trialJohn F DiPersio, Guenther Koehne, Nirali N Shah, et al.
Transplantation and Cellular Therapy|March 22, 2022
Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell TransplantationSagar S Patel, Kwang Woo Ahn, Manoj Khanal, et al.
British Journal of Haematology|June 14, 2021
Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantationCarolyn M Mulroney, Muhammad Bilal Abid, Asad Bashey, et al.
Blood Advances|October 5, 2019
Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancyScott R Solomon, Andrew St Martin, Nirav N Shah, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Cancer|April 6, 2023
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myelomaNaresh Bumma, Binod Dhakal, Raphael Fraser, et al.
Cancer Discovery|April 7, 2024
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell CarcinomaSumanta K Pal, Ben Tran, John B A G Haanen, et al.
Blood|December 12, 2025
Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trialEverett Meyer, Amandeep Salhotra, Arpita Gandhi, et al.
Blood|March 3, 2026
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomaJennifer L Crombie, Sairah Ahmed, Matthew J Frigault, et al.
Transplantation and Cellular Therapy|September 29, 2021
Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic SyndromeAnurag Singh, Christopher E Dandoy, Min Chen, et al.
JCO Precision Oncology|October 23, 2025
Remission of <i>TP53</i>-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33)Guenther Koehne, Muhammad U Mushtaq, Lori S Muffly, et al.
Nature Medicine|May 12, 2026
CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trialJohn F DiPersio, Guenther Koehne, Nirali N Shah, et al.
Transplantation and Cellular Therapy|March 22, 2022
Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell TransplantationSagar S Patel, Kwang Woo Ahn, Manoj Khanal, et al.
British Journal of Haematology|June 14, 2021
Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantationCarolyn M Mulroney, Muhammad Bilal Abid, Asad Bashey, et al.
Blood Advances|October 5, 2019
Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancyScott R Solomon, Andrew St Martin, Nirav N Shah, et al.
Pageof 5